Paul van der Bijl specialises in ECM transactions, public M&A, corporate governance of listed companies, anti-takeover defences and complex cross-border transactions.
Paul has acted as issuer’s counsel in the Nasdaq IPOs of CureVac, Centogene, InflaRx, trivago, Playa Hotels & Resorts, Mylan, ProQR Therapeutics and Cnova, the Euronext Amsterdam IPOs of Unibail-Rodamco-Westfield, a.s.r., ForFarmers, Sif and Cnova and the Frankfurt Stock Exchange IPO of Instone Real Estate. He has also acted as shareholder’s counsel or underwriters’ counsel, as applicable, in the Nasdaq IPOs of Merus and Affimed and the Euronext Amsterdam IPOs of Basic-Fit and Kiadis Pharma. Paul represents Mylan in the (pending) $22bn strategic combination of Mylan and Pfizer's Upjohn division and Mylan's $7.2 billion offer for Meda.
Paul is recommended for public M&A by Legal500 and lectures on anti-takeover defences at the postgraduate specialization course of the Radboud University (Grotius).